BSGM — Biosig Technologies Income Statement
0.000.00%
Last trade - 00:00
- $15.79m
- $15.63m
- $0.02m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.441 | 0.286 | 0.018 |
Cost of Revenue | |||||
Gross Profit | — | — | 0.242 | 0.229 | 0.018 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 34.6 | 59.2 | 33.3 | 27.6 | 28.5 |
Operating Profit | -34.6 | -59.2 | -32.9 | -27.3 | -28.5 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -34.5 | -59.1 | -32.9 | -27.3 | -28.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -34.5 | -59.1 | -32.9 | -27.3 | -28.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -34.1 | -52.2 | -31.9 | -27.1 | -29 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -34.1 | -52.2 | -31.9 | -27.3 | -29.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -16.5 | -18.7 | -9.69 | -6.4 | -3.95 |